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S U M M A R Y
Background: The present study is one of the ﬁrst to provide a picture of antimicrobial resistance for a
range of bacteria and antimicrobial classes in Gabon, Central Africa.
Methods: During the year 2010, 146 urine cytology, 143 blood cultures, 107 vaginal swabs, 23 urethral
swabs, and 18 other culture examinations were positives. All isolates were tested for antibiotic sensitivity.
Results: Four hundred thirty-seven microorganisms were isolated: 210 enterobacteria, 166 staphylo-
cocci, 38 streptococci, 14 Acinetobacter, and nine Stenotrophomonas. Of the Klebsiella isolates, 18% and
30% were found to be resistant to selected third-generation cephalosporins (3CG) and fourth-generation
cephalosporins (4CG), respectively. Sixty-seven percent of Escherichia coli isolates were resistant to
amoxicillin with clavulanic acid. Between 3% and 30% of E. coli isolates were resistant to selected 3CG. All
Enterobacter cloacae isolates were sensitive to imipenem. Resistance to quinolones/ﬂuoroquinolones was
seen in 21–50% of E. coli isolates. Twenty-six percent of E. cloacae showed resistance to ceftazidime and
37% to cefotaxime. The resistance rate to quinolones ranged between 58% and 78%. Thirty-two percent of
Staphylococcus isolates were resistant to gentamicin. Low resistance rates to teicoplanin (2–4%) were
observed. Thirty-seven percent of isolated Staphylococcus aureus and 61% of isolated Staphylococcus
saprophyticus were resistant to both penicillin G and oxacillin. Streptococcus isolates had low resistance
rates to erythromycin, ceftriaxone, and ciproﬂoxacin (5%, 7%, and 14%, respectively) and were highly
resistant to tetracycline, gentamicin, and sulfamethoxazole–trimethoprim (92%, 91%, and 62%,
respectively).
Conclusions: The antimicrobial resistance proﬁles seen here are of concern. To control the spread of
drug-resistant bacteria, clinicians should be cognizant of their local antimicrobial resistance patterns.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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In developing countries, the spread of antimicrobial resistance
is a matter of concern as its compromises the management of
infectious diseases, the leading causes of morbidity and death in
these countries.1–3 Existing data show that there is an association
between antimicrobial resistance and increased mortality, mor-
bidity, and healthcare costs.4–6
The excessive use of antimicrobials produces selective pressure
for resistance.7,8 Also, empirical treatment with ineffective
antibiotics prescribed by physicians and poor patient adherence* Corresponding author.
E-mail address: joelﬂeury@yahoo.com (J.F. Djoba Siawaya).
http://dx.doi.org/10.1016/j.ijid.2014.01.015
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).to antibiotic regimens could potentially lead to mutation and drug
resistance.7,8 Furthermore, the routine use of antibiotics in animal
foods to promote their growth is another aspect that may enhance
selective pressure for resistance.9,10
Roberts et al., reported that signiﬁcant health and economic
beneﬁts could be realized through effective interventions to reduce
antimicrobial-resistant infections.6 Antibiotic susceptibility test-
ing is a key indicator in the design of effective interventions for
rational antibiotic use.11,12 The reporting of antibiotic susceptibili-
ty testing results by clinical laboratories is required for the
surveillance of emerging resistance and the development of
appropriate prescription guidelines.6,8,11–13
Our study is one of the ﬁrst and unique efforts to provide a
broad picture of antimicrobial resistance for a range of bacteria
and antimicrobial classes in Central Africa (Gabon). Resistance tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Antibiotics used for sensitivity testing
Penicillins Penicillin G (P)
Amoxicillin (AMX)
Amoxicillin with clavulanic acid (AMC)
Oxacillin (OX)
Ticarcillin (TIC)
Ticarcillin–clavulanic acid (TCC)
Piperacillin (PIP)
Piperacillin–tazobactam (TZP)
Monobactams Aztreonam (ATM)
First-generation cephalosporins Cefalotin (CF)
Second-generation cephalosporins Cefuroxime (CXM or FUR)
Cefoxitin (FOX)
Third-generation cephalosporins Cefotaxime (CTX)
Ceftazidime (CAZ)
Ceftriaxone (CRO)
Fourth-generation cephalosporins Cefepime (FEP)
Aminoglycosides Kanamycin (K)
Gentamicin (GM)
Tobramycin (TOB)
Netilmicin (NET)
Amikacin (AN)
Fosfomycin Fosfomycin (FOS)
Rifampin Rifampin (RA)
Phenicols Chloramphenicol (C)
Quinolones/ﬂuoroquinolones Nalidixic acid (NA)
Norﬂoxacin (NOR)
Pleﬂoxacin (PEF)
Oﬂoxacin (OFX)
Ciproﬂoxacin (CIP)
Levoﬂoxacin (LEV)
Macrolides Lincomycin (L)
Erythromycin (E)
Clindamycin (CC)
Spiramycin (SP)
Pristinamycin (PR)
Glycopeptides Vancomycin (VA)
Teicoplanin (TEC)
Sulfonamides and associates Sulfamethoxazole with trimethoprim
(SXT)
Triple sulfa (SSS)
Trimethoprim (TMP)
Tetracyclines Minocycline (MNO)
Tetracycline (TE)
Others Colistin (CS)
Fusidic acid (FA)
Linezolid (LNZ)
Minocycline (MNO)
Nitrofurantoin (FT)
Telithromycin (TEL)
Imipenem (IPM)
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cephalosporins (4CG), macrolides, penicillin, quinolones, sulfona-
mides and associates, tetracycline, and others were assessed for
Enterobacteriaceae, staphylococci, and streptococci.
2. Methods
This study was carried out at the Gabonese National Laboratory
of Public Health in Libreville. The National Laboratory of Public
Health is the largest laboratory among the few in the country
equipped to carry out bacteriological tests. We believe that the
data presented here represent the situation in Libreville (over 40%
of the Gabonese population lives in Libreville). The National
Laboratory of Public Health managed 9035 patients in its
bacteriology service in 2010. Hospitalized patients represented
12% and ambulant patients 88% of patients seen.
Four hundred thirty-seven microorganisms were isolated from
146 urine cultures, 143 blood cultures, 107 vaginal swabs,
23 urethral swabs, and 18 other culture examinations. All isolated
organisms were tested for antibiotic sensitivity (the list of
antibiotics tested is given in Table 1).
The identiﬁcation of microorganisms was done using bioMe´r-
ieux API bacterial identiﬁcation test strips (bioMe´rieux, France). All
tests were done in accordance with the manufacturer’s instruc-
tions and protocols. bioMe´rieux API 20E or API 10S strips
(bioMe´rieux, France) were used for the identiﬁcation of Enter-
obacteriaceae, whereas staphylococci and streptococci were
identiﬁed by bioMe´rieux API kits for Micrococcaceae (Slidex kits
were used for the conﬁrmation of Staphylococcus aureus). The
analysis of antibiotic resistance was done in accordance with the
French Society of Microbiology guidelines. Sensitivity testing was
done using both bioMe´rieux ATB test strips (ATB G, ATB UR, ATB-
Staph, and ATB-Strep; bioMe´rieux, France) and the BioRad agar
disk diffusion method (BioRad, Marnes-la-Coquette, France). High-
level aminoglycosides were used for Streptococcus sensitivity
testing. Resistance to amoxicillin, aztreonam, and at least two of
the following antibiotics: cefuroxime, ceftazidime, cefotaxime,
ceftriaxone, and cefepime, was an indicator of probable extended-
spectrum beta-lactamase (ESBL) strains,14–16 whereas resistance
to both penicillin G and oxacillin indicated a methicillin-resistant-
like proﬁle.17
All patients gave their consent after being informed that the
results of their antimicrobial sensitivity testing would be reported
for scientiﬁc and epidemiological surveillance purposes. The
review board of the National Laboratory of Public Health approved
the study protocol.
3. Results and discussion
Resistance to antimicrobial agents has become a major
healthcare problem. Clinicians should be cognizant of their local
antimicrobial resistance patterns in order to be more efﬁcient in
dealing with bacterial infections and to prevent the spread of drug-
resistant bacteria. The present study is the ﬁrst to provide a picture
of antimicrobial resistance for a range of bacteria and antimicrobial
classes in Central Africa, particularly in Gabon.
In this study, 437 microorganisms were isolated: 210 enter-
obacteria, 166 staphylococci, 38 streptococci, 14 Acinetobacter,
and nine Stenotrophomonas (detailed in Table 2). Observed
sensitivity proﬁles are shown in Tables 3–5.
Enterobacteriaceae are among the leading causes of community-
onset bacterial infections.3 Beta-lactams and ﬂuoroquinolones are
the principal antibiotic classes used to treat enterobacteria
infections. Here we found that a quarter of isolated Klebsiella
spp were resistant to amoxicillin with clavulanic acid. Klebsiella spp
resistance to gentamicin and cephalosporins is of concern. Morethan half of the isolated Klebsiella spp were resistant to gentamicin;
18%, 30%, 26%, 33%, 51%, 60%, and 79% of isolated Klebsiella spp were
resistant to cefepime (4CG), tazobactam (beta-lactamase inhibi-
tor), ceftazidime (3CG), cefotaxime (3CG), cefoxitin (2CG),
cefuroxime (2CG), and cefalotin (1CG), respectively; 18%, 28%,
32%, and 54% of isolates were resistant to ciproﬂoxacin, oﬂoxacin,
norﬂoxacin, and nalidixic acid, respectively. All isolates of Klebsiella
spp were sensitive to the carbapenem antibiotic imipenem. Our
data suggest that in our setting selected ﬂuoroquinolones/
quinolones and selected fourth- and third-generation cephalos-
porins could be more effective than gentamicin, but less effective
than imipenem in treating Klebsiella spp infections.15
For a number of antibiotics, we found that the rates of resistant
strains of Escherichia coli in our setting were higher than those
reported in other studies.18–20 Ninety-one percent of isolates were
resistant to amoxicillin; the resistance rate to the combination
amoxicillin and clavulanic acid was 66%. Imipenem, aztreonam
(3CG), amikacin, and ceftazidime (3CG) maintained high activity;
more than 85% of E. coli isolates were sensitive to these antibiotics.
The same results were observed in other studies.21,22 Resistance to
Table 2
Microorganism isolates and samples of origin
Microorganism Urine Culture Vaginal Swab Culture Urethral Swab Culture Blood culture Stool Culture Other Total
Enterobacteriaceae 210
Citrobacter braakii 1 1
Citrobacter diversus 2 2
Citrobacter farmeri 1 1
Citrobacter freundii 3 9 12
Citrobacter koseri 6 3 9
Enterobacter aerogenes 2 1 3
Enterobacter cloacae 3 24 27
E. coli 34 3 37
E. coli 1 9 9
E. vulneris 2 1 3
Klebsiella ornithinolytica 1 1
Klebsiella oxytoca 5 4 9
Klebsiella pneumoniae 15 31 46
Klebsiella pneumoniae ssp 7 15 22
Klebsiella spp 1 1
Morganella morganii 2 1 3
Proteus mirabilis 1 1
Proteus vulgaris 1 1
Pseudomonas aeruginosa 1 3 4
Salmonella spp 2 2
Serratia liquefaciens 1 1
Serratia marcescens 2 2 4
Serratia odorifera 7 3 10
Yersinia enterolytica 1 0 0 0 0 0 1
Staphylococci 166
S. aureus 9 62 11 12 6 7 107
S. saprophyticus 23 14 12 5 3 57
S. epidermidis 1 1 2
Streptococci 39
Enterococcus feacalis 1 2 1 1 5
Streptococcus agalactiae 1 25 26
Group C Streptococcus 1 1
Group F Streptococcus 2 2
Streptococcus spp 1 1 2
Group G Streptococcus 1 1 2
Acinetobacter baumannii 4 10 14
Stenotrophomonas maltophilia 9 9
Total 146 107 23 143 6 12 437
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isolates were resistant to nalidixic acid, a third to oﬂoxacin and
norﬂoxacin, and a quarter to a ﬁfth were resistant to ciproﬂoxacin.
Resistance to nalidixic acid, a marker of the development of
ﬂuoroquinolone tolerance,23 was found in half of the E. coli isolates
in our setting, indicating a move towards ﬂuoroquinolone
resistance. The resistance proﬁle of Enterobacter cloacae is alarming
as the only molecules with an activity above 70% were fosfomycin
and imipenem. Only imipenem had good activity against Serratia
odorifera. Although the carbapenem (imipenem) had good activity
on a number of Enterobacteriaceae, about a seventh of Citrobacter
freundii were resistant to it. Overall, for the selected antibiotics, the
resistance proﬁle of Enterobacteriaceae in our study is comparable
to that seen in Southeast Asia.14 Furthermore, about a third of
Enterobacteriaceae showed an antibiotic resistance proﬁle common
with the ESBL strains.
About 80% of Acinetobacter baumannii isolates were sensitive to
piperacillin–tazobactam, amikacin, and ceftazidime. Half of the A.
baumannii isolates were resistant to imipenem. This observation is
consistent with those of previous reports in the literature.24,25
Staphylococci are a common cause of invasive infections. The
adaptability of staphylococci is one of the reasons why antibiotics
should not be prescribed systematically. In the current study,
Staphylococcus isolates were resistant to penicillin G. Also the
sensitivity to teicoplanin was quite high (approximately 90%).
More than 70% of isolated staphylococci were resistant totetracyclines. Thirty-seven percent of S. aureus and 61% of
Staphylococcus saprophyticus were resistant to oxacillin. Also
observed was resistance to aminoglycosides (32.5% gentamicin-
and 45.5% tobramycin-resistant isolates). Thirty-seven percent of
isolated staphylococci were resistant to both penicillin G and
oxacillin, indicating a methicillin-resistant-like proﬁle,17 which is
close to the ﬁndings of Groome et al. in South Africa.1
Penicillins are the ﬁrst choice for the prophylactic treatment
of streptococci, followed by cefazolin, a ﬁrst-generation cepha-
losporin. Here we found that 25% and 41% of isolated streptococci
were resistant to amoxicillin and penicillin G, respectively. These
observed resistance rates are relatively high compared to those
seen elsewhere26 and demand caution from medical prescribers.
Clindamycin, erythromycin, and vancomycin are also recom-
mended for the treatment of streptococci.27,28 In the setting of
the Gabonese National Laboratory of Public Health, the preva-
lence of isolates resistant to the macrolide clindamycin is notably
high (46%). Rifampin, vancomycin, erythromycin, and to an
extent ceftriaxone (third-generation cephalosporin) appear to be
adequate for the treatment of streptococci in the Gabonese
setting, as our data show low rates or an absence of resistance
for these molecules. However, one should foresee that the
7%, 14%, 22%, and the 46% of isolates resistant to erythromycin,
ciproﬂoxacin (ﬂuoroquinolone), spiramycin (macrolide), and
clindamycin, respectively, may represent the start of future
public health challenges in the country. The high resistance rates
Table 3
Enterobacteriaceae, Acinetobacter, and Stenotrophomonas resistance and sensitivity rates expressed in percentages
Antibiotics Klebsiella spp
(n=79)
Escherichia coli
(n =46)
Enterobacter spp
(n=30)
Serratia odorifera
(n=15)
Acinetobacter
baumannii
(n =14)
Citrobacter
freundii
(n =11)
Citrobacter
koseri
(n=9)
Stenotrophomonas
maltophilia
(n=9)
R S I R S I R S I R S I R S I R S I R S I R S I
AMX 100 - - 91 9 - 100 - - 100 - - 100 - - 100 - - 100 - - 100 - -
AMC 23 75 1 67 16 18 100 - - 100 - - 92 8 - 100 - - 89 11 - 100 - -
TIC 100 - - 92 8 - 69 28 3 93 7 - 64 36 - 67 33 - 100 - - 100 - -
TCC 67 32 2 58 33 8 61 36 4 79 21 - 44 56 - 64 36 - 78 22 - 100 - -
PIP 100 - - 80 20 - 56 44 - 80 20 - 50 50 - 60 40 - 100 - - 100 - -
TZP 30 63 7 21 74 5 15 85 - 27 64 9 12.5 87.5 - 36 45.5 18 50 25 25 60 40 -
CF 79 16 5 63 18 19 100 - - 87 - 13 100 - - 94 - 6 86 - 14 100 - -
CXM 60 33 6 30 54.5 15 77 18 4.5 78 22 - 100 - - 86 7 7 86 14 - 100 - -
FOX 51 46 3 29 62 9 100 - - 67 33 - 92 8 - 100 - - 86 14 - - - -
CTX 33 54 13 20 76 4 37 60 3 36 64 - 57 21 21 28 57 14 67 17 17 100 - -
CAZ 26 56 18 12 78 10 26 63 11 21 64 14 15 77 8 62.5 6 29 43 30 20 60 20
FEP 18 61 21 17 70 3 15 70 15 30 50 20 - 57 43 - 78 22 - - - - - -
ATM - - - 3 97 - - - - - - - 80 20 - - - - - - - - - -
IPM - 100 - - 100 - - 100 - - 100 - 50 50 - 15 85 - - 100 - 100 - -
GM 56.5 40.5 3 36 64 - 44 56 - 46 54 - 54.5 45.5 - 38.5 61.5 - 50 50 - 100 - -
TOB 55 42 3 32 68 - 38.5 61.5 - 36 64 - 54.5 45.5 - 40 60 - 60 40 - 100 - -
NET 51 45.5 3.5 31 67 2 38 62 - 38.5 61.5 - 38.5 61.5 - 38.5 61.5 0 56 44 - 100 - -
AN 34 65 1 6 90 3 35 65 - 40 60 - 12.5 87.5 - 21 79 0 0 100 - 11 89 -
NA 54 46 50 50 0 78 22 - 60 40 - 64 36 - 64 36 0 60 40 - 22 78 -
NOR 32 65 3 31 61.5 7.5 67 33 - 53 40 7 44 44 11 40 60 0 37.5 60 2.5 22 78 -
OFX 28 63 9 31 69 60 40 - 47 40 13 25 58 17 36 64 - 29 71 - 22 78 -
CIP 18 76 6 21 76 3 58 42 - 27 60 13 25 58 17 33 67 - 29 71 - 22 78 -
FOS 54 46 - 28 71 1 21 79 - 47 53 - 60 40 - 12.5 87.5 - 100 - - 100 - -
RA - - - - - - - - - - - - 100 - - - - - - - - - - -
FT - - - - - - 36 43 21 - - - 60 20 20 20 80 - 100 - - - - -
SXT 62 48 - 83 7 - 81 14 5 47 53 - 82 18 - 64 36 - 67 33 - 67 23 -
R, resistant; S, sensitive; I, intermediate; AMX, amoxicillin; AMC, amoxicillin with clavulanic acid; TIC, ticarcillin; TCC, ticarcillin–clavulanic acid; PIP, piperacillin; TZP, piperacillin/tazobactam; CF, cefalotin; CXM, cefuroxime; FOX,
cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; GM, gentamicin; TOB, tobramycin; NET, netilmicin; AN, amikacin; NA, nalidixic Acid; NOR, norﬂoxacin; OFX, oﬂoxacin; CIP,
ciproﬂoxacin; FOS, fosfomycin; RA, rifampin; FT, nitrofurantoin; SXT, sulfamethoxazole with trimethoprim.
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Table 5
Streptococcus resistance and sensitivity rates expressed in percentages
Antibiotics Streptococcus spp (n = 33)
R S I
P 41 59 -
AMX 25 75 -
OX 23 77 -
GM 91 4.5 4.5
C 20 80 -
TE 92 8 -
E 7 80 3.3
CC 46 54 -
SXT 62 38 -
RA - 96 4
VA - 90 10
TEC - 80 20
SP 22 78 -
CIP 14 86 -
CRO 5 90 5
OFX 40 60 -
R, resistant; S, sensitive; I, intermediate; P, penicillin G; AMX, amoxicillin; OX,
oxacillin; GM, gentamicin; C, chloramphenicol; TE, tetracycline; E, erythromycin;
CC, clindamycin; SXT, sulfamethoxazole with trimethoprim; RA, rifampin; VA,
vancomycin; TEC, teicoplanin; SP, spiramycin; CIP, ciproﬂoxacin; CRO, ceftriaxone;
OFX, oﬂoxacin.
Table 4
Staphylococcus resistance and sensitivity rates expressed in percentages
Antibiotics Staphylococcus
aureus (n = 107)
Staphylococcus
saprophyticus (n = 57)
R S I R S I
P 100 - - 100 - -
OX 37 63 - 61 39 -
TOB 45.5 54.5 - - - -
AN 26.5 70.5 3 25 85 -
GM 32.5 64 3.5 32 68 -
TE 71 29 - 79 21 -
E 34 66 - 56 44 -
VA - 95 5 - 94.5 5.5
TEC 2 91.5 6 4 87.5 8.5
RA 8 89 2 12.5 87.5 -
FOS 18.5 81.5 - 96 4 -
FA 23.5 76.5 - 23.5 76.5 -
PEF 36 64 - 55.5 45.5 -
R, resistant; S, sensitive; I, intermediate; P, penicillin G; OX, oxacillin; TOB,
tobramycin; AN, amikacin; GM, gentamicin; TE, tetracycline; E, erythromycin; VA,
vancomycin; TEC, teicoplanin; RA, rifampin; FOS, fosfomycin; FA, fusidic acid; PEF,
pleﬂoxacin.
L. Kouegnigan Rerambiah et al. / International Journal of Infectious Diseases 29 (2014) 48–5352to sulfamethoxazole with trimethoprim and tetracycline (62%
and 92%, respectively) observed are in line with previously
reported rates and support the avoidance of sulfonamide and
tetracycline use in the treatment of streptococci.28,29
Furthermore, the level of vancomycin-intermediate suscepti-
bility phenotype observed in this study commands caution despite
the fact that we could not conﬁrm these results due to the data
reported coming from a retrospective analysis of national
laboratory routine testing.
The report by Nys et al.30 shows us that in some respects,
antibiotic resistance proﬁles are different from one developing
country to another. Also, the prescribing practice of clinicians
giving patients antibiotics before culture results become available
and patient self-medication are thought to be the principal causes
of the present situation.31,32
In conclusion, the choice of appropriate antibiotic therapy
remains a challenge for the physician; they should be aware of the
local epidemiology of antimicrobial resistance to properly guide
their prescriptions for antibacterial therapy.
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